SCHEMBL169363

SCHEMBL169363

Cc1ccc(C2CCN(Cc3ccccc3)CC2)nc1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.60
DRD4 P21917 8/20 0.60
DRD3 P35462 7/20 0.60
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.55
ACHE P22303 3/20 0.54
BACE1 P56817 2/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CCR3 P51677 1/20 0.49
BCHE P06276 1/20 0.48
HRH1 P35367 1/20 0.48
SIGMAR1 Q99720 1/20 0.47
HPGDS O60760 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2636322 0.93 BCHE (0.53) DRD2DRD4DRD3LMNAPOLB
SCHEMBL13490598 0.87 CYP2D6 (0.51) DRD2DRD4DRD3LMNAPOLB
SCHEMBL13490548 0.84 DRD4 (0.52) DRD2DRD4DRD3ACHEBACE1
SCHEMBL13490551 0.84 DRD2 (0.52) DRD2DRD4DRD3ACHEBACE1
SCHEMBL171620 0.84 HPGDS (0.55) DRD2DRD4DRD3ACHECCR3
SCHEMBL12068366 0.82 ACHE (0.57) DRD2DRD4DRD3LMNAPOLB
SCHEMBL171680 0.81 DRD2 (0.61) DRD2DRD4DRD3ACHEBACE1
SCHEMBL13490679 0.81 HRH3 (0.55) DRD2DRD4DRD3ACHE
SCHEMBL6195713 0.81 DRD4 (0.59) DRD2DRD4DRD3ACHEMEN1
SCHEMBL171290 0.80 DRD4 (0.52) DRD2DRD4DRD3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530662-B2 Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2013-09-10 US disclosed
US-8530662-B2 Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2013-09-10 US disclosed
EP-2426120-A1 Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them Fujifilm Finechemicals Co., Ltd. (JP) 2012-03-07 EP disclosed
US-20100029947-A1 Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them FUJIFILM FINECHEMICALS CO., LTD 2010-02-04 US disclosed
US-20100029947-A1 Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them FUJIFILM FINECHEMICALS CO., LTD 2010-02-04 US disclosed
US-7632950-B2 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2009-12-15 US disclosed
US-7632950-B2 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2009-12-15 US disclosed
US-20070093528-A1 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2007-04-26 US disclosed
US-20070093528-A1 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them FUJIFILM FINECHEMICALS CO., LTD (JP) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029947-A1 Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them QDPR, HRH4, HRH2 DRD2 130/4885DRD4 112/4885DRD3 448/4885
US-20070093528-A1 Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them QDPR, HRH4, HRH2 DRD2 112/4885DRD4 107/4885DRD3 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.